Le site du DES d'oncologie de Toulouse

Sénologie

8 articles et 1 document

Articles
Trastuzumab Deruxtecan in PreviouslyTreated HER2-Positive Breast Cancer
Sénologie - Publié le 22/01/2020 par Ilfad Blazevic

BACKGROUND
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an
anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapep-
tide-based linke... lire la suite


Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Sénologie - Publié le 22/01/2020 par Ilfad Blazevic

BACKGROUND
Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic
breast cancer who have disease progression after therapy with multiple HER2-targeted
agents ha... lire la suite


MONALEESA : Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor – Positive, Human Epidermal Growth Factor Receptor 2 – Negative Advanced Breast Cancer
Sénologie - Publié le 01/08/2019 par Céline Dalmasso

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor – Positive, Human Epidermal Growth Factor Receptor 2 – Negative Advanced Breast Cancer: MONALEESA-3... lire la suite


MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Sénologie - Publié le 01/08/2019 par Céline Dalmasso

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer... lire la suite


EMBRACE: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Sénologie - Publié le 01/08/2019 par Céline Dalmasso

Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study... lire la suite


Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Sénologie - Publié le 01/08/2019 par Céline Dalmasso

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOM... lire la suite


VELIPARIB with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patietns with BRCA1/2 locally recurrent/metastatix breast cancer: randomized phase II study
Sénologie - Publié le 23/04/2019 par Céline Dalmasso

essai BROCADE... lire la suite


Dissecting the heterogeneity of triple negative breast cancer
Sénologie - Publié le 23/04/2019 par Céline Dalmasso

... lire la suite